AAPL $343.46 +0.82% ▲ ACN $229.68 +2.12% ▲ ADBE $245.20 -2.12% ▼ ADEA $20.42 -5.02% ▼ ADIG $15.48 -1.40% ▼ ADP $288.90 +1.14% ▲ ADSK $239.90 -1.68% ▼ AEHR $60.60 -10.88% ▼ AEVA $10.03 -8.98% ▼ AGYS $109.90 -3.10% ▼ AI $11.32 -6.68% ▼ AIP $18.76 -6.20% ▼ ALAB $285.82 -4.37% ▼ ALKT $13.73 -3.51% ▼ ALNT $92.64 -4.48% ▼ AMBA $61.70 -2.45% ▼ AMBQ $49.88 -5.87% ▼ AMD $528.75 -4.47% ▼ AMPL $14.75 -6.82% ▼ AMZN $250.00 -1.28% ▼ ANET $176.98 -4.40% ▼ AOSL $21.75 -6.81% ▼ APLD $18.05 -10.78% ▼ APP $266.13 -4.30% ▼ APPN $41.17 -6.00% ▼ APPS $9.56 -8.95% ▼ ARM $227.80 -6.18% ▼ ARRY $3.43 -4.30% ▼ ARW $214.61 -2.43% ▼ ASML $1,641.52 -0.38% ▼ AAPL $343.46 +0.82% ▲ ACN $229.68 +2.12% ▲ ADBE $245.20 -2.12% ▼ ADEA $20.42 -5.02% ▼ ADIG $15.48 -1.40% ▼ ADP $288.90 +1.14% ▲ ADSK $239.90 -1.68% ▼ AEHR $60.60 -10.88% ▼ AEVA $10.03 -8.98% ▼ AGYS $109.90 -3.10% ▼ AI $11.32 -6.68% ▼ AIP $18.76 -6.20% ▼ ALAB $285.82 -4.37% ▼ ALKT $13.73 -3.51% ▼ ALNT $92.64 -4.48% ▼ AMBA $61.70 -2.45% ▼ AMBQ $49.88 -5.87% ▼ AMD $528.75 -4.47% ▼ AMPL $14.75 -6.82% ▼ AMZN $250.00 -1.28% ▼ ANET $176.98 -4.40% ▼ AOSL $21.75 -6.81% ▼ APLD $18.05 -10.78% ▼ APP $266.13 -4.30% ▼ APPN $41.17 -6.00% ▼ APPS $9.56 -8.95% ▼ ARM $227.80 -6.18% ▼ ARRY $3.43 -4.30% ▼ ARW $214.61 -2.43% ▼ ASML $1,641.52 -0.38% ▼

Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?

October 1, 2026 · by TPW Pipeline

As healthcare costs and procedure volumes continue to shift globally, investors must decide between two titans of the industry. Choosing between Abbott Laboratories (NYSE:ABT) and Intuitive Surgical (NASDAQ:ISRG) requires weighing diversified stability against high-growth specialized technology.

Abbott provides a broad array of medical products used in daily care, while Intuitive focuses on the specialized niche of robotic-assisted surgery. These companies are often compared because they represent different ways to invest in the future of medical technology and hospital spending.

Abbott Laboratories operates a diversified business model that spans diabetes care, cardiovascular devices, diagnostics, and nutrition. It sells products to a wide range of customers, including hospitals, wholesalers, and government agencies, which helps it weather fluctuations in any single market. In early 2026, the company entered a definitive agreement to acquire Exact Sciences to strengthen its presence in the cancer diagnostics market.

Continue reading

Source: www.fool.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.